N@N

Simulations Plus Releases Major Upgrade in ADMET Predictor 5.0

^{Published on 2010-07-27 05:12:33 - Market Wire}
 

LANCASTER, Calif.--([ BUSINESS WIRE ])--Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, has released a major upgrade for its best-in-class ADMET Predictora" software for predicting properties of molecules with only their structures as inputs.

Dr. Robert Fraczkiewicz, team leader for ADMET Cheminformatics at Simulations Plus, said, aThis new release of ADMET Predictor, Version 5.0, is the result of over a year of work that builds upon our Small Business Innovation Research grant from the National Institutes of Health, as well as many man-months of work under our internally funded R&D. ADMET Predictor was already ranked at the top of every independent published comparison study in predictive accuracy, and we are confident this upgrade will build on that success and expand our competitive advantage in the marketplace.a

ADMET Predictor Version 5.0 incorporates:

• A series of new predictive models that broaden the scope of the offering
• Completely retrained existing models with further improved accuracy
• New and updated molecular and atomic descriptors used in training the models
• A number of convenience improvements to the user interface
• New output options for better visualization of results
• Improved model-building capabilities in its ADMET Modelera" module

Walt Woltosz, chairman and chief executive officer of Simulations Plus, added, aThis new release of ADMET Predictor is important not only for what the program can do by itself, but also because it integrates with two of our other major software offerings and thereby enhances three products rather than just one. GastroPlusa" and MedChem Studioa" (formerly ClassPharmera") both can call ADMET Predictor in the background to generate predicted properties for use in their respective analyses. We are confident ADMET Predictora™s advantage over the competition has now been extended even further with version 5.0.a

About Simulations Plus, Inc.

Simulations Plus, Inc. is a premier developer of groundbreaking drug discovery and development simulation and modeling software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. The Companya™s Words+, Inc., wholly owned subsidiary provides augmentative communication systems and other technologies for persons with disabilities. Simulations Plus is headquartered in Southern California. For more information, visit our web site at [ www.simulations-plus.com ].

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995a" With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like abelieve,a aexpecta and aanticipatea mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the Securities and Exchange Commission.